SmallCap Sentinel: The Ex-Stent of Progress


IRVINE, Calif., Oct. 24, 2007 (PRIME NEWSWIRE) -- "In the rapidly changing world of biotechnology new ideas are plied and tried with enthusiasm. But few of these medical notions will find themselves as far along as MIV Therapeutics, Inc. (OTCBB:MIVT) which has posted news twice this week regarding its polymer-free stent sending a signal to investors that the company is making enormous progress," stated SmallCap Sentinel analyst D.R. Clark.

A comprehensive report focusing on MIV Therapeutics, Inc. and developments in cardiovascular stents and drug delivery has been published by financial courier StockUpTicks.com and is available free of charge to the general public. The report will feature detailed information regarding MIVT and address related information and stent companies including Johnson & Johnson (NYSE:JNJ), Medtronic Inc. (NYSE:MDT), and Boston Scientific (NYSE:BSX).

To view the report in its entirety, please visit:

http://stockupticks.com/profiles/10-16-07.html

"This week alone, MIV has released impressive news, the first of which on Monday reported positive results from the first human study with its VESTASYNC stent as the Principal Investigator Alexandre Abizaid, M.D., Ph.D., Chief of Coronary Intervention of Institute Dante Pazzanese of Cardiology in Sao Paulo, Brazil, noted excellent safety data with no Major Adverse Coronary Events (MACE), and good efficacy data," said Clark. "This was followed by an announcement Tuesday that Dr. Abizaid performed one live four-month follow-up case from the MIVT pilot trial at the Transcatheter Cardiovascular Therapeutics (TCT) 2007 conference yesterday, during which angiographic, IVUS and OCT studies were conducted."

"This is a strong showcase for MIV and it's significant that they are greeting their industry peers at a time when positive events abound," Clark added. "It sends a strong signal to the industry and investors."

MIV Therapeutics Inc. is focused on commercializing the next generation of fully biocompatible coatings for cardiovascular stents and drug delivery systems to treat coronary artery disease, an estimated $6 billion worldwide market.

The SmallCap Sentinel logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=3664

Statements herein contain forward-looking statements and are subject to significant risks and uncertainties affecting results. SmallCap Sentinel/StockUpTicks.com are properties of Market Pathways Financial Relations Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect proposed actions and cannot project capabilities, intent, resources, or experience.

All information contained herein is based upon sources believed to be reliable but no representation is made as to accuracy or completeness. This report is neither a solicitation to buy nor an offer to sell securities but is rather a paid advertisement provided for information purposes only and shouldn't be used as basis for any investment decision. MP is not an investment advisor and this report is not investment advice. MP has been paid $24,000 by MIV Therapeutics for preparation and distribution of this report and other advertising services over a ninety day period. This constitutes a conflict of interest as to MP's ability to remain objective in its communication regarding the subject company.



            

Contact Data